1. Search Result
Search Result
Results for "

STI

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

6

Inhibitory Antibodies

2

Recombinant Proteins

5

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15463
    Imatinib
    Maximum Cited Publications
    120 Publications Verification

    STI571; CGP-57148B

    Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib
  • HY-50946
    Imatinib Mesylate
    Maximum Cited Publications
    120 Publications Verification

    STI571 Mesylate; CGP-57148B Mesylate

    c-Kit Bcr-Abl PDGFR Autophagy Infection Neurological Disease Inflammation/Immunology Cancer
    Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
    Imatinib Mesylate
  • HY-156655A

    STI-1558 sodium

    SARS-CoV Cathepsin Virus Protease Infection
    Olgotrelvir (STI-1558) sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
    Olgotrelvir sodium
  • HY-15463S1

    STI571 d4; CGP-57148B d4

    Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
    Imatinib-d4
  • HY-15463S
    Imatinib-d8
    1 Publications Verification

    STI571-d8; CGP-57148B-d8

    Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
    Imatinib-d8
  • HY-P99594

    ZKAB001; STI-1014; STI-A1014

    PD-1/PD-L1 Cancer
    Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
    Socazolimab
  • HY-P991057

    CD47 Cancer
    STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    STI-6643
  • HY-156655

    STI-1558

    SARS-CoV Virus Protease Cathepsin Infection
    Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
    Olgotrelvir
  • HY-15463R

    STI571 (Standard); CGP-57148B (Standard)

    Reference Standards Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib (Standard)
  • HY-50946R

    STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)

    Reference Standards c-Kit Bcr-Abl PDGFR Autophagy Cancer
    Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
    Imatinib Mesylate (Standard)
  • HY-15463S3

    STI571-13C,d3; CGP-57148B-13C,d3

    Isotope-Labeled Compounds Autophagy SARS-CoV Bcr-Abl PDGFR c-Kit Cancer
    Imatinib- 13C,d3 (STI571- 13C,d3) is 13C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib-13C,d3
  • HY-RS17458

    Small Interfering RNA (siRNA) Others

    Aars1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Aars1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Aars1 Mouse Pre-designed siRNA Set A
    Aars1 Mouse Pre-designed siRNA Set A
  • HY-P990014

    IMC-001; STI-3031

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
    Danburstotug
  • HY-168550

    ADC Linker Cancer
    STI-8811 drug-linker is a linker for synthesis of ADC molecule STI-8811 .
    STI-8811 drug-linker
  • HY-111849

    CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding moiety 1

    Ligands for Target Protein for PROTAC Cancer
    Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .
    Imatinib carbaldehyde
  • HY-15463S2

    STI571-d3 hydrochloride; CGP-57148B-d3 hydrochloride

    Autophagy Bcr-Abl c-Kit SARS-CoV PDGFR Cancer
    Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
    Imatinib-d3 hydrochloride
  • HY-P99104

    COVI-AMG; STI-2020

    SARS-CoV Infection
    Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
    Plutavimab
  • HY-P991877

    ADC Antibody CD3 Cancer
    STI-8811 Antibody is an anti-human BCMA antibody. STI-8811 Antibody can generate antibody drug conjugate (ADC) (STI-8811) with an auristatin derivative, Duostatin 5 (HY-145149). STI-8811 Antibody can be used for the study of multiple myeloma .
    STI-8811 Antibody
  • HY-131275

    Drug Metabolite Others
    Imatinib Impurity E is the impurity of Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib Impurity E
  • HY-P992468

    STI-1110
  • HY-132386S
    Imatinib-d8 mesylate
    1 Publications Verification

    STI571-d8 mesylate; CGP-57148B-d8 mesylate

    Isotope-Labeled Compounds Others
    Imatinib-d8 (mesylate) is the deuterium labeled Imatinib mesylate .
    Imatinib-d8 mesylate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: